



# Third Congress of the ICMC May 23<sup>rd</sup>, 2022, Paris, France

## Abstract

### **Contraceptive Efficacy and Acceptability in Couples using a Hormonal Male Contraceptive Method**

**Diana Blithe, PhD,**

Senior Scientist and Chief, Contraceptive Development Program (CDP), National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), USA

Men and women express strong interest in using an effective, reversible male contraceptive product to avoid unintended pregnancy.

The Contraceptive Development Program, NICHD, in collaboration with the Population Council, has developed a male hormonal method that effectively inhibits sperm production. The gel product containing two hormones, Nestorone® (a potent progestin) and Testosterone, is currently under evaluation in a Phase IIb efficacy clinical trial in couples using the method to avoid pregnancy. The trial is ongoing in the CDP Contraceptive Clinical Trials Network sites in the USA, Europe, Chile and Kenya. Perspectives from participating couples reveals how important a method of male contraception is to their family planning needs.

This Phase IIb clinical trial in couples is the most advanced stage of development for any effective user-controlled male contraceptive method. Interim results demonstrate high efficacy, acceptability and reversibility. The results strongly support a safe and successful product profile that may allow the product to proceed to Phase III pivotal evaluation.